Andrew Murray

Company: Sania Therapeutics

Job title: Chief Executive Officer and Founder

Seminars:

Human-Evolved AAV Vectors to Access Specific Neural Circuits 10:45 am

Targeting specific components of the nervous system provides a gateway to safely treat numerous disorders that have a high unmet need Our novel technology platform, R-Scan, recreates human neural circuits and allows us to evolve novel AAV vectors specifically targeted to those cell types Our first use case has been in motor neurons, and our…Read more

day: Conference Day Two